Pre-clinical models for immunotherapy of melanoma.
Reisfeld
R A
RA
Department of Immunology, Scripps Clinic and Research Foundation, La Jolla, California 92037.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000951:Antigens, Neoplasm; D002448:Cell Adhesion; D005732:Gangliosides / Q000276:immunology / Q000502:physiology; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000637:transplantation; D008545:Melanoma / Q000276:immunology / Q000628:therapy; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy*; D058950:Melanoma-Specific Antigens; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000276:immunology / Q000502:physiology; D009447:Neuroblastoma / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D005732:Gangliosides; D007376:Interleukin-2; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins